XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]    
Revenues
Operating Expenses:    
Research and development 11,906,601 14,819,729
General and administrative 18,249,402 15,295,584
Stock-based compensation – general and administrative 11,839,678 6,616,705
Total Operating Expenses 41,995,681 36,732,018
Operating Loss (41,995,681) (36,732,018)
Other Income:    
Interest income, net 758,000 1,179,417
Gain on sale of New Jersey net operating losses 2,387,842 3,585,689
Total Other Income Net 3,145,842 4,765,106
Loss before Income Taxes (38,849,839) (31,966,912)
Income tax expense 576,000 576,000
Net Loss (39,425,839) (32,542,912)
Net loss attributable to non-controlling interest 287,000
Deemed dividend on warrant extension (1,047,312) (1,151,208)
Net Loss Applicable to Common Stockholders $ (40,186,151) $ (33,694,120)
Net Loss Per Share Applicable to Common Stockholders - Basic (in Dollars per share) $ (5.97) $ (5.57)
Net Loss Per Share Applicable to Common Stockholders - Diluted (in Dollars per share) $ (5.97) $ (5.57)
Weighted Average Common Shares Outstanding    
Basic weighted Average Common Shares Outstanding (in Shares) 6,726,999 6,051,789
Diluted Weighted average common shares outstanding (in Shares) 6,726,999 6,051,789